During the last session, Prelude Therapeutics Inc (NASDAQ:PRLD)’s traded shares were 0.46 million, with the beta value of the company hitting 1.38. At the end of the trading day, the stock’s price was $1.39, reflecting an intraday gain of 11.20% or $0.14. The 52-week high for the PRLD share is $6.80, that puts it down -389.21 from that peak though still a striking 42.45% gain since the share price plummeted to a 52-week low of $0.80. The company’s market capitalization is $76.49M, and the average intraday trading volume over the past 10 days was 0.96 million shares, and the average trade volume was 471.96K shares over the past three months.
Prelude Therapeutics Inc (PRLD) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 3.00. PRLD has a Sell rating from 2 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it.
Prelude Therapeutics Inc (NASDAQ:PRLD) trade information
Prelude Therapeutics Inc (PRLD) registered a 11.20% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 11.20% in intraday trading to $1.39, hitting a weekly high. The stock’s 5-day price performance is -0.71%, and it has moved by 41.59% in 30 days. Based on these gigs, the overall price performance for the year is -63.23%. The short interest in Prelude Therapeutics Inc (NASDAQ:PRLD) is 3.26 million shares and it means that shorts have 8.17 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 72.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, PRLD is trading at a discount of -259.71% off the target high and -259.71% off the low.
Prelude Therapeutics Inc (PRLD) estimates and forecasts
Statistics show that Prelude Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Prelude Therapeutics Inc (PRLD) shares have gone down -61.39% during the last six months, with a year-to-date growth rate less than the industry average at 10.40% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.14%. While earnings are projected to return 12.13% in 2025, the next five years will return 30.10% per annum.
PRLD Dividends
Prelude Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders
Prelude Therapeutics Inc insiders own 9.36% of total outstanding shares while institutional holders control 84.98%, with the float percentage being 93.76%. ORBIMED ADVISORS LLC is the largest shareholder of the company, while 101.0 institutions own stock in it. As of 2024-06-30, the company held over 10.91 million shares (or 14.4043% of all shares), a total value of $41.56 million in shares.
The next largest institutional holding, with 10.12 million shares, is of BAKER BROS. ADVISORS LP’s that is approximately 13.3673% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $38.57 million.
